Free Trial
→ $100 Trillion “AI Metal” Found in American Ghost Town (From Brownstone Research) (Ad)tc pixel Free FLGT Stock Alerts

Fulgent Genetics (FLGT) Financials

Fulgent Genetics logo
$23.74 +0.12 (+0.51%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$24.66 +0.92 (+3.85%)
As of 10/24/2025 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Fulgent Genetics

Annual Income Statements for Fulgent Genetics

This table shows Fulgent Genetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 143 -168 -43
Consolidated Net Income / (Loss)		 142 -175 -44
Net Income / (Loss) Continuing Operations		 142 -175 -44
Total Pre-Tax Income 		184 -174 -52
Total Operating Income		 179 -196 -74
Total Gross Profit		 367 104 107
Total Revenue		 619 289 283
Operating Revenue		 619 289 283
Total Cost of Revenue		 252 185 176
Operating Cost of Revenue		 252 185 176
Total Operating Expenses		 188 300 181
Selling, General & Admin Expense		 111 89 88
Marketing Expense		 39 41 36
Research & Development Expense		 29 41 49
Amortization Expense		 6.50 7.85 7.97
Impairment Charge		 0.00 120 0.00
Restructuring Charge		 2.98 0.00 0.00
Total Other Income / (Expense), net		 5.50 21 22
Interest Expense		 - - -0.17
Interest & Investment Income		 5.62 22 31
Other Income / (Expense), net		 0.89 0.32 -9.51
Income Tax Expense		 42 1.15 -8.14
Net Income / (Loss) Attributable to Noncontrolling Interest		 -1.48 -7.41 -1.11
Weighted Average Basic Shares Outstanding		 30.10M 29.78M 30.24M
Weighted Average Diluted Shares Outstanding		 30.96M 29.78M 30.24M
Weighted Average Basic & Diluted Shares Outstanding		 29.52M 29.78M 30.83M

Quarterly Income Statements for Fulgent Genetics

This table shows Fulgent Genetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 1.72 -24 -15 -11 -13 -128 -13 -8.71 -15 -5.89
Consolidated Net Income / (Loss)		 1.34 -24 -16 -12 -13 -134 -14 -9.09 -15 -6.19
Net Income / (Loss) Continuing Operations		 1.34 -24 -16 -12 -13 -134 -14 -9.09 -15 -6.19
Total Pre-Tax Income 		1.76 -33 -21 -15 6.86 -145 -14 -11 -19 -8.04
Total Operating Income		 0.35 -37 -25 -20 0.21 -151 -22 -19 -17 -16
Total Gross Profit		 46 13 19 21 40 25 22 26 27 32
Total Revenue		 106 68 66 68 85 71 64 71 72 76
Operating Revenue		 106 68 66 68 85 71 64 71 72 76
Total Cost of Revenue		 60 55 47 47 45 45 42 45 45 44
Operating Cost of Revenue		 60 55 47 47 45 45 42 45 45 44
Total Operating Expenses		 46 50 44 40 40 176 44 45 44 48
Selling, General & Admin Expense		 26 29 22 18 17 32 21 21 21 24
Marketing Expense		 9.86 10 10 11 10 11 8.99 8.60 9.12 9.54
Research & Development Expense		 7.51 8.51 9.78 9.69 10 12 11 13 12 12
Amortization Expense		 2.01 2.01 1.97 1.96 1.96 1.96 1.99 1.99 1.99 1.99
Total Other Income / (Expense), net		 1.41 3.09 3.78 5.10 6.65 5.93 7.63 7.69 -1.45 8.10
Interest & Investment Income		 1.41 3.22 3.78 5.10 6.47 6.27 7.63 7.69 8.09 7.90
Income Tax Expense		 0.41 -9.39 -5.20 -3.11 20 -11 -0.33 -2.12 -3.84 -1.85
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.38 -0.24 -0.51 -0.36 -0.36 -6.19 -0.38 -0.38 -0.05 -0.30
Weighted Average Basic Shares Outstanding		 30.17M 30.10M 29.54M 29.81M 30.01M 29.78M 29.77M 30.10M 30.42M 30.24M
Weighted Average Diluted Shares Outstanding		 30.87M 30.96M 29.54M 29.81M 30.01M 29.78M 29.77M 30.10M 30.42M 30.24M
Weighted Average Basic & Diluted Shares Outstanding		 29.44M 29.52M 29.70M 29.93M 29.63M 29.78M 29.92M 30.30M 30.59M 30.83M

Annual Cash Flow Statements for Fulgent Genetics

This table details how cash moves in and out of Fulgent Genetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -85 18 -42
Net Cash From Operating Activities		 254 27 21
Net Cash From Continuing Operating Activities		 254 27 21
Net Income / (Loss) Continuing Operations		 142 -175 -44
Consolidated Net Income / (Loss)		 142 -175 -44
Depreciation Expense		 33 26 25
Amortization Expense		 4.77 -3.91 -5.55
Non-Cash Adjustments To Reconcile Net Income		 60 177 61
Changes in Operating Assets and Liabilities, net		 14 2.82 -15
Net Cash From Investing Activities		 -261 39 -58
Net Cash From Continuing Investing Activities		 -261 39 -58
Purchase of Property, Plant & Equipment		 -19 -22 -40
Acquisitions		 -183 -0.40 0.00
Purchase of Investments		 -418 -492 -472
Sale of Property, Plant & Equipment		 0.41 0.78 0.31
Sale and/or Maturity of Investments		 373 553 454
Other Investing Activities, net		 -15 0.00 0.00
Net Cash From Financing Activities		 -77 -48 -4.85
Net Cash From Continuing Financing Activities		 -77 -48 -4.85
Repayment of Debt		 -0.37 -4.27 -1.23
Repurchase of Common Equity		 -74 -25 -0.23
Other Financing Activities, net		 -2.44 -18 -3.39
Effect of Exchange Rate Changes		 -0.45 -0.15 -0.06
Cash Interest Paid		 0.00 0.96 0.51
Cash Income Taxes Paid		 56 3.26 28

Quarterly Cash Flow Statements for Fulgent Genetics

This table details how cash moves in and out of Fulgent Genetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 30 -89 -13 -7.82 26 13 -43 10 -6.93 -2.90
Net Cash From Operating Activities		 21 33 -7.91 9.74 10 15 7.27 4.29 -16 25
Net Cash From Continuing Operating Activities		 21 33 -7.91 9.74 10 15 7.27 4.29 -16 25
Net Income / (Loss) Continuing Operations		 1.34 -24 -16 -12 -13 -134 -14 -9.09 -15 -6.19
Consolidated Net Income / (Loss)		 1.34 -24 -16 -12 -13 -134 -14 -9.09 -15 -6.19
Depreciation Expense		 9.82 9.80 6.88 6.31 6.42 6.53 6.66 6.15 5.92 6.19
Amortization Expense		 1.01 0.54 -0.48 -0.71 -1.19 -1.53 -1.18 -1.49 -1.34 -1.55
Non-Cash Adjustments To Reconcile Net Income		 17 6.87 10 15 6.67 145 9.77 17 19 15
Changes in Operating Assets and Liabilities, net		 -8.58 40 -8.47 0.24 12 -0.76 5.86 -8.16 -25 12
Net Cash From Investing Activities		 44 -93 -4.35 -1.10 20 24 -47 7.30 8.99 -27
Net Cash From Continuing Investing Activities		 44 -93 -4.35 -1.10 20 24 -47 7.30 8.99 -27
Purchase of Property, Plant & Equipment		 -5.44 -4.72 -2.03 -12 -4.92 -3.11 -4.06 -13 -20 -3.78
Purchase of Investments		 -12 -146 -144 -107 -93 -148 -196 -63 -115 -98
Sale and/or Maturity of Investments		 61 108 141 117 118 176 152 83 144 75
Net Cash From Financing Activities		 -35 -30 -1.10 -16 -4.47 -26 -2.81 -1.15 -0.57 -0.33
Net Cash From Continuing Financing Activities		 -35 -30 -1.10 -16 -4.47 -26 -2.81 -1.15 -0.57 -0.33
Other Financing Activities, net		 -0.76 -0.54 -1.10 -15 14 -16 -1.82 -0.68 -0.57 -0.33
Effect of Exchange Rate Changes		 0.39 -0.28 0.03 -0.21 -0.12 0.15 -0.07 -0.01 0.16 -0.13
Cash Interest Paid		 - - 0.00 0.92 0.02 0.02 0.44 0.01 0.01 0.05
Cash Income Taxes Paid		 1.20 0.01 1.68 0.96 0.06 0.56 1.31 0.60 25 0.95

Annual Balance Sheets for Fulgent Genetics

This table presents Fulgent Genetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 1,386 1,235 1,220
Total Current Assets		 628 508 354
Cash & Equivalents		 80 97 55
Short-Term Investments		 447 327 203
Accounts Receivable		 53 51 69
Other Current Assets		 49 33 26
Plant, Property, & Equipment, net		 81 83 106
Total Noncurrent Assets		 677 644 761
Long-Term Investments		 339 444 570
Goodwill		 143 22 22
Intangible Assets		 151 143 135
Other Noncurrent Operating Assets		 44 35 33
Total Liabilities & Shareholders' Equity		 1,386 1,235 1,220
Total Liabilities		 116 102 91
Total Current Liabilities		 88 73 73
Short-Term Debt		 21 1.18 0.41
Accounts Payable		 23 15 18
Accrued Expenses		 25 31 24
Customer Deposits		 11 23 28
Current Deferred Revenue		 3.20 2.87 2.23
Other Current Liabilities		 5.30 0.16 0.00
Total Noncurrent Liabilities		 28 29 18
Noncurrent Deferred & Payable Income Tax Liabilities		 9.84 14 11
Other Noncurrent Operating Liabilities		 18 15 6.97
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,270 1,133 1,129
Total Preferred & Common Equity		 1,267 1,136 1,133
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 1,267 1,136 1,133
Common Stock		 487 502 543
Retained Earnings		 801 633 590
Accumulated Other Comprehensive Income / (Loss)		 -21 1.21 -0.37
Noncontrolling Interest		 3.19 -2.82 -4.07

Quarterly Balance Sheets for Fulgent Genetics

This table presents Fulgent Genetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 1,406 1,377 1,355 1,358 1,230 1,232 1,234
Total Current Assets		 697 581 528 550 387 399 327
Cash & Equivalents		 169 66 58 84 55 65 58
Short-Term Investments		 402 438 400 384 251 247 155
Accounts Receivable		 104 44 35 49 52 57 57
Other Current Assets		 21 33 35 33 29 31 56
Plant, Property, & Equipment, net		 82 79 88 85 87 93 107
Total Noncurrent Assets		 627 717 739 723 757 740 800
Long-Term Investments		 358 380 401 399 561 547 602
Goodwill		 120 143 142 142 22 22 22
Intangible Assets		 88 149 146 144 141 139 137
Other Noncurrent Operating Assets		 61 45 49 38 33 32 39
Total Liabilities & Shareholders' Equity		 1,406 1,377 1,355 1,358 1,230 1,232 1,234
Total Liabilities		 124 108 91 97 103 103 99
Total Current Liabilities		 103 82 65 61 76 76 74
Short-Term Debt		 20 5.61 4.56 2.89 0.41 0.41 0.41
Accounts Payable		 14 22 21 16 20 20 20
Accrued Expenses		 25 21 22 21 26 26 24
Customer Deposits		 26 12 14 19 27 26 27
Current Deferred Revenue		 2.60 2.73 2.60 2.59 2.76 2.74 2.97
Other Current Liabilities		 14 19 0.36 0.28 0.00 0.00 0.00
Total Noncurrent Liabilities		 22 26 26 35 27 28 25
Noncurrent Deferred & Payable Income Tax Liabilities		 1.83 9.84 9.84 19 13 13 13
Other Noncurrent Operating Liabilities		 20 16 17 16 14 14 12
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,281 1,269 1,263 1,262 1,127 1,129 1,135
Total Preferred & Common Equity		 1,277 1,264 1,260 1,259 1,130 1,133 1,138
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,277 1,264 1,260 1,259 1,130 1,133 1,138
Common Stock		 478 496 506 514 511 522 533
Retained Earnings		 825 786 774 761 620 611 596
Accumulated Other Comprehensive Income / (Loss)		 -26 -17 -21 -17 -1.10 -0.88 9.18
Noncontrolling Interest		 4.35 4.47 3.56 3.14 -3.30 -3.70 -3.55

Annual Metrics And Ratios for Fulgent Genetics

This table displays calculated financial ratios and metrics derived from Fulgent Genetics' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 -37.64% -53.28% -1.99%
EBITDA Growth		 -68.78% -179.77% 62.97%
EBIT Growth		 -73.46% -208.80% 57.26%
NOPAT Growth		 -72.55% -199.41% 62.20%
Net Income Growth		 -71.97% -223.47% 74.99%
EPS Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -52.93% -89.35% -22.01%
Free Cash Flow Firm Growth		 -111.56% 146.06% -492.19%
Invested Capital Growth		 77.44% -37.38% 13.07%
Revenue Q/Q Growth		 -22.91% 0.98% 2.06%
EBITDA Q/Q Growth		 -45.60% -223.97% 66.14%
EBIT Q/Q Growth		 -50.97% -141.12% 60.06%
NOPAT Q/Q Growth		 -48.61% -141.51% 64.62%
Net Income Q/Q Growth		 -47.37% -169.68% 74.52%
EPS Q/Q Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -14.75% -40.36% 91.89%
Free Cash Flow Firm Q/Q Growth		 -198.91% 126.87% -27.02%
Invested Capital Q/Q Growth		 14.12% -33.11% -5.90%
Profitability Metrics		 - - -
Gross Margin		 59.28% 36.12% 37.82%
EBITDA Margin		 35.03% -59.81% -22.60%
Operating Margin		 28.84% -67.61% -26.08%
EBIT Margin		 28.99% -67.50% -29.43%
Profit (Net Income) Margin		 22.93% -60.59% -15.46%
Tax Burden Percent		 77.12% 100.66% 84.34%
Interest Burden Percent		 102.57% 89.18% 62.28%
Effective Tax Rate		 22.88% 0.00% 0.00%
Return on Invested Capital (ROIC)		 41.41% -39.58% -18.24%
ROIC Less NNEP Spread (ROIC-NNEP)		 40.94% -35.10% -19.17%
Return on Net Nonoperating Assets (RNNOA)		 -29.76% 25.00% 14.36%
Return on Equity (ROE)		 11.65% -14.58% -3.87%
Cash Return on Invested Capital (CROIC)		 -14.41% 6.38% -30.51%
Operating Return on Assets (OROA)		 13.47% -14.89% -6.80%
Return on Assets (ROA)		 10.65% -13.37% -3.57%
Return on Common Equity (ROCE)		 11.60% -14.58% -3.89%
Return on Equity Simple (ROE_SIMPLE)		 11.20% -15.42% -3.87%
Net Operating Profit after Tax (NOPAT)		 138 -137 -52
NOPAT Margin		 22.24% -47.33% -18.25%
Net Nonoperating Expense Percent (NNEP)		 0.48% -4.48% 0.93%
Return On Investment Capital (ROIC_SIMPLE)		 10.67% -12.06% -4.58%
Cost of Revenue to Revenue		 40.72% 63.88% 62.18%
SG&A Expenses to Revenue		 17.95% 30.77% 31.08%
R&D to Revenue		 4.67% 14.33% 17.22%
Operating Expenses to Revenue		 30.43% 103.72% 63.90%
Earnings before Interest and Taxes (EBIT)		 179 -195 -83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 217 -173 -64
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.69 0.75 0.50
Price to Tangible Book Value (P/TBV)		 0.90 0.88 0.58
Price to Revenue (P/Rev)		 1.42 2.96 1.99
Price to Earnings (P/E)		 6.11 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 16.36% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.08 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.06 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.16 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.20 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.26 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.14 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.02 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -0.73 -0.71 -0.75
Leverage Ratio		 1.09 1.09 1.09
Compound Leverage Factor		 1.12 0.97 0.68
Debt to Total Capital		 1.60% 0.10% 0.04%
Short-Term Debt to Total Capital		 1.60% 0.10% 0.04%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.25% -0.25% -0.36%
Common Equity to Total Capital		 98.15% 100.14% 100.32%
Debt to EBITDA		 0.10 -0.01 -0.01
Net Debt to EBITDA		 -3.90 5.01 12.93
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.15 -0.01 -0.01
Net Debt to NOPAT		 -6.13 6.33 16.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 6.68 5.89 4.69
Noncontrolling Interest Sharing Ratio		 0.42% 0.02% -0.30%
Liquidity Ratios		 - - -
Current Ratio		 7.13 6.96 4.85
Quick Ratio		 6.57 6.51 4.49
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -48 22 -87
Operating Cash Flow to CapEx		 1,380.60% 125.99% 52.65%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.46 0.22 0.23
Accounts Receivable Turnover		 6.46 5.57 4.72
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 8.62 3.51 3.00
Accounts Payable Turnover		 11.57 9.61 10.45
Days Sales Outstanding (DSO)		 56.51 65.55 77.36
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 31.56 37.98 34.92
Cash Conversion Cycle (CCC)		 24.95 27.57 42.44
Capital & Investment Metrics		 - - -
Invested Capital		 425 266 301
Invested Capital Turnover		 1.86 0.84 1.00
Increase / (Decrease) in Invested Capital		 186 -159 35
Enterprise Value (EV)		 35 -13 -267
Market Capitalization		 877 857 565
Book Value per Share		 $43.03 $38.34 $37.05
Tangible Book Value per Share		 $33.05 $32.77 $31.92
Total Capital		 1,291 1,134 1,130
Total Debt		 21 1.18 0.41
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -845 -867 -828
Capital Expenditures (CapEx)		 18 21 40
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 34 12 23
Debt-free Net Working Capital (DFNWC)		 560 436 281
Net Working Capital (NWC)		 540 435 281
Net Nonoperating Expense (NNE)		 -4.24 38 -7.92
Net Nonoperating Obligations (NNO)		 -845 -867 -828
Total Depreciation and Amortization (D&A)		 37 22 19
Debt-free, Cash-free Net Working Capital to Revenue		 5.52% 4.10% 8.11%
Debt-free Net Working Capital to Revenue		 90.54% 150.76% 99.16%
Net Working Capital to Revenue		 87.20% 150.35% 99.01%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 29.78M 30.24M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 29.78M 30.24M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 29.78M 30.83M
Normalized Net Operating Profit after Tax (NOPAT)		 140 -53 -52
Normalized NOPAT Margin		 22.61% -18.22% -18.25%
Pre Tax Income Margin		 29.73% -60.19% -18.33%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 52.38% -14.30% -0.51%

Quarterly Metrics And Ratios for Fulgent Genetics

This table displays calculated financial ratios and metrics derived from Fulgent Genetics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -53.63% -73.10% -79.34% -45.87% -19.85% 4.14% -2.54% 4.68% -15.28% 8.10%
EBITDA Growth		 -93.22% -116.75% -108.83% -163.25% -49.13% -457.42% 11.42% -0.27% -487.25% 92.14%
EBIT Growth		 -99.78% -124.23% -112.29% -254.74% 30.11% -313.44% 12.19% 4.51% -5,909.61% 89.32%
NOPAT Growth		 -99.78% -124.67% -111.32% -234.21% -256.13% -313.44% 12.19% 4.51% -2,745.98% 89.32%
Net Income Growth		 -98.90% -123.22% -110.32% -204.42% -1,102.68% -457.96% 12.64% 21.57% -9.12% 95.39%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -86.35% -56.92% -104.20% -12.48% -50.71% -55.03% 191.89% -55.99% -251.46% 67.54%
Free Cash Flow Firm Growth		 -533.41% -1,373.31% -634.00% 77.26% 88.19% 125.17% 162.09% 355.41% 355.50% -186.73%
Invested Capital Growth		 143.34% 77.44% 74.88% 9.29% 6.83% -37.38% -33.26% -33.63% -19.62% 13.07%
Revenue Q/Q Growth		 -15.71% -35.92% -2.27% 2.55% 24.81% -16.75% -8.54% 10.15% 1.01% 6.23%
EBITDA Q/Q Growth		 -50.21% -334.48% 29.72% 22.92% 140.05% -2,669.32% 88.83% 12.75% -54.67% 47.84%
EBIT Q/Q Growth		 -97.25% -10,484.09% 32.09% 20.25% 102.31% -33,095.85% 85.58% 13.27% -40.74% 39.36%
NOPAT Q/Q Growth		 -97.39% -9,609.60% 32.09% 20.25% 96.97% -25,082.25% 85.58% 13.27% 9.66% 5.53%
Net Income Q/Q Growth		 -87.90% -1,892.70% 34.17% 26.87% -16.19% -897.58% 89.69% 34.35% -61.65% 57.87%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 86.73% 59.83% -123.81% 223.14% 5.17% 45.83% -51.34% -41.03% -461.94% 261.31%
Free Cash Flow Firm Q/Q Growth		 -2.63% 3.67% 12.65% 73.67% 46.70% 305.33% 115.48% 8.30% -46.68% -169.70%
Invested Capital Q/Q Growth		 -0.24% 14.12% -8.23% 4.61% -2.48% -33.11% -2.21% 4.04% 18.11% -5.90%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 43.63% 19.18% 28.43% 30.32% 47.05% 35.78% 34.28% 37.30% 37.32% 41.79%
EBITDA Margin		 10.58% -38.72% -27.84% -20.93% 6.72% -207.24% -25.31% -20.05% -30.70% -15.07%
Operating Margin		 0.33% -53.99% -37.52% -29.18% 0.25% -214.34% -33.80% -26.62% -23.81% -21.17%
EBIT Margin		 0.33% -53.99% -37.52% -29.18% 0.54% -214.34% -33.80% -26.62% -37.09% -21.17%
Profit (Net Income) Margin		 1.27% -35.56% -23.95% -17.08% -15.90% -190.53% -21.47% -12.80% -20.48% -8.12%
Tax Burden Percent		 76.44% 71.95% 75.30% 78.84% -196.30% 92.52% 97.69% 81.06% 79.29% 77.02%
Interest Burden Percent		 499.15% 91.55% 84.79% 74.25% 1,497.82% 96.08% 65.02% 59.31% 69.65% 49.81%
Effective Tax Rate		 23.56% 0.00% 0.00% 0.00% 296.30% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.78% -70.36% -31.24% -16.06% -0.37% -125.50% -20.91% -15.95% -12.89% -14.81%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.66% -70.53% -31.40% -16.31% 1.10% -122.16% -21.07% -16.43% -12.56% -15.41%
Return on Net Nonoperating Assets (RNNOA)		 -0.51% 51.28% 23.94% 11.36% -0.77% 87.01% 15.35% 11.77% 8.80% 11.54%
Return on Equity (ROE)		 0.27% -19.08% -7.30% -4.70% -1.14% -38.49% -5.56% -4.18% -4.09% -3.26%
Cash Return on Invested Capital (CROIC)		 18.43% -14.41% -65.49% -23.35% -21.31% 6.38% -1.52% 0.93% -18.98% -30.51%
Operating Return on Assets (OROA)		 0.20% -25.08% -9.63% -6.37% 0.11% -47.30% -7.46% -5.98% -7.95% -4.89%
Return on Assets (ROA)		 0.78% -16.52% -6.15% -3.73% -3.30% -42.04% -4.74% -2.88% -4.39% -1.88%
Return on Common Equity (ROCE)		 0.27% -19.00% -7.27% -4.68% -1.13% -38.48% -5.56% -4.18% -4.09% -3.27%
Return on Equity Simple (ROE_SIMPLE)		 21.12% 0.00% -2.17% -3.98% -5.16% 0.00% -15.33% -15.08% -15.11% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.27 -26 -17 -14 -0.42 -106 -15 -13 -12 -11
NOPAT Margin		 0.25% -37.79% -26.26% -20.42% -0.50% -150.04% -23.66% -18.63% -16.66% -14.82%
Net Nonoperating Expense Percent (NNEP)		 0.12% 0.17% 0.16% 0.25% -1.47% -3.34% 0.16% 0.48% -0.33% 0.60%
Return On Investment Capital (ROIC_SIMPLE)		 - -1.98% - - - -9.32% - - - -1.00%
Cost of Revenue to Revenue		 56.37% 80.82% 71.57% 69.68% 52.95% 64.22% 65.72% 62.70% 62.68% 58.21%
SG&A Expenses to Revenue		 24.86% 42.53% 32.95% 26.52% 20.66% 44.97% 33.32% 30.02% 29.20% 31.94%
R&D to Revenue		 7.11% 12.57% 14.78% 14.28% 11.82% 16.95% 17.73% 18.99% 16.42% 15.89%
Operating Expenses to Revenue		 43.29% 73.17% 65.95% 59.50% 46.80% 250.12% 68.08% 63.91% 61.12% 62.96%
Earnings before Interest and Taxes (EBIT)		 0.35 -37 -25 -20 0.46 -151 -22 -19 -27 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 11 -26 -18 -14 5.69 -146 -16 -14 -22 -11
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.90 0.69 0.73 0.87 0.64 0.75 0.57 0.52 0.58 0.50
Price to Tangible Book Value (P/TBV)		 1.08 0.90 0.95 1.13 0.82 0.88 0.67 0.60 0.67 0.58
Price to Revenue (P/Rev)		 1.44 1.42 2.53 3.58 2.79 2.96 2.24 2.02 2.37 1.99
Price to Earnings (P/E)		 4.25 6.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 23.54% 16.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.67 0.08 0.12 0.61 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.31 0.06 0.13 0.81 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.63 0.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.68 0.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.93 0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.84 0.14 0.83 4.45 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 5.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.02 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.77 -0.73 -0.76 -0.70 -0.70 -0.71 -0.73 -0.72 -0.70 -0.75
Leverage Ratio		 1.12 1.09 1.10 1.09 1.09 1.09 1.09 1.08 1.08 1.09
Compound Leverage Factor		 5.60 1.00 0.93 0.81 16.28 1.05 0.71 0.64 0.75 0.54
Debt to Total Capital		 1.57% 1.60% 0.44% 0.36% 0.23% 0.10% 0.04% 0.04% 0.04% 0.04%
Short-Term Debt to Total Capital		 1.57% 1.60% 0.44% 0.36% 0.23% 0.10% 0.04% 0.04% 0.04% 0.04%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.33% 0.25% 0.35% 0.28% 0.25% -0.25% -0.29% -0.33% -0.31% -0.36%
Common Equity to Total Capital		 98.09% 98.15% 99.21% 99.36% 99.52% 100.14% 100.26% 100.29% 100.28% 100.32%
Debt to EBITDA		 0.05 0.10 -0.51 -0.10 -0.05 -0.01 0.00 0.00 0.00 -0.01
Net Debt to EBITDA		 -2.28 -3.90 79.84 17.94 16.18 5.01 5.06 5.01 4.31 12.93
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.08 0.15 -0.17 -0.08 -0.05 -0.01 0.00 0.00 0.00 -0.01
Net Debt to NOPAT		 -3.39 -6.13 26.03 15.11 15.24 6.33 6.43 6.40 5.57 16.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 7.47 6.16 6.57 8.62 6.40 6.01 4.92 4.60 5.07 4.88
Noncontrolling Interest Sharing Ratio		 0.52% 0.42% 0.44% 0.37% 0.29% 0.02% 0.05% -0.01% -0.02% -0.30%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 6.79 7.13 7.09 8.15 8.95 6.96 5.09 5.27 4.41 4.85
Quick Ratio		 6.59 6.57 6.69 7.61 8.42 6.51 4.71 4.86 3.65 4.49
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -219 -211 -184 -49 -26 53 115 124 66 -46
Operating Cash Flow to CapEx		 398.54% 729.82% -430.66% 81.66% 208.94% 538.90% 191.31% 33.15% -79.54% 662.20%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -369.82 0.00 0.00 0.00 4,724.34 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 146.29 0.00 0.00 0.00 -1,107.79 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 76.27 0.00 0.00 0.00 -2,500.57 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.62 0.46 0.26 0.22 0.21 0.22 0.22 0.22 0.21 0.23
Accounts Receivable Turnover		 7.14 6.46 3.58 3.66 3.73 5.57 6.01 6.36 5.21 4.72
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 11.31 8.62 4.94 3.54 3.43 3.51 3.47 3.21 2.89 3.00
Accounts Payable Turnover		 13.19 11.57 9.69 7.24 12.84 9.61 8.62 8.75 9.96 10.45
Days Sales Outstanding (DSO)		 51.14 56.51 101.94 99.81 97.77 65.55 60.68 57.37 70.04 77.36
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 27.67 31.56 37.68 50.42 28.43 37.98 42.33 41.73 36.65 34.92
Cash Conversion Cycle (CCC)		 23.46 24.95 64.26 49.39 69.34 27.57 18.36 15.64 33.39 42.44
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 373 425 390 408 398 266 260 271 320 301
Invested Capital Turnover		 3.05 1.86 1.19 0.79 0.74 0.84 0.88 0.86 0.77 1.00
Increase / (Decrease) in Invested Capital		 220 186 167 35 25 -159 -130 -137 -78 35
Enterprise Value (EV)		 249 35 47 248 -60 -13 -226 -274 -160 -267
Market Capitalization		 1,154 877 922 1,100 800 857 643 587 658 565
Book Value per Share		 $42.19 $43.03 $42.84 $42.41 $42.06 $38.34 $37.96 $37.85 $37.58 $37.05
Tangible Book Value per Share		 $35.32 $33.05 $32.95 $32.70 $32.49 $32.77 $32.48 $32.47 $32.32 $31.92
Total Capital		 1,302 1,291 1,275 1,268 1,265 1,134 1,127 1,129 1,135 1,130
Total Debt		 20 21 5.61 4.56 2.89 1.18 0.41 0.41 0.41 0.41
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -909 -845 -879 -855 -864 -867 -866 -858 -815 -828
Capital Expenditures (CapEx)		 5.21 4.55 1.84 12 4.90 2.77 3.80 13 19 3.78
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 44 34 -0.09 9.60 24 12 5.28 12 40 23
Debt-free Net Working Capital (DFNWC)		 615 560 504 468 491 436 311 324 253 281
Net Working Capital (NWC)		 594 540 499 463 488 435 311 323 253 281
Net Nonoperating Expense (NNE)		 -1.07 -1.51 -1.53 -2.27 13 29 -1.41 -4.14 2.74 -5.10
Net Nonoperating Obligations (NNO)		 -909 -845 -879 -855 -864 -867 -866 -858 -815 -828
Total Depreciation and Amortization (D&A)		 11 10 6.40 5.60 5.23 5.00 5.48 4.67 4.59 4.65
Debt-free, Cash-free Net Working Capital to Revenue		 5.42% 5.52% -0.03% 3.12% 8.21% 4.10% 1.84% 4.15% 14.36% 8.11%
Debt-free Net Working Capital to Revenue		 76.54% 90.54% 138.24% 152.26% 171.54% 150.76% 108.15% 111.37% 91.07% 99.16%
Net Working Capital to Revenue		 73.99% 87.20% 136.70% 150.78% 170.54% 150.35% 108.01% 111.23% 90.92% 99.01%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 30.17M 30.10M 29.54M 29.81M 30.01M 29.78M 29.77M 30.10M 30.42M 30.24M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 30.87M 30.96M 29.54M 29.81M 30.01M 29.78M 29.77M 30.10M 30.42M 30.24M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 29.44M 29.52M 29.70M 29.93M 29.63M 29.78M 29.92M 30.30M 30.59M 30.83M
Normalized Net Operating Profit after Tax (NOPAT)		 0.35 -26 -17 -14 0.15 -106 -15 -13 -12 -11
Normalized NOPAT Margin		 0.33% -37.82% -26.26% -20.42% 0.18% -150.04% -23.66% -18.63% -16.66% -14.82%
Pre Tax Income Margin		 1.66% -49.42% -31.81% -21.66% 8.10% -205.94% -21.98% -15.79% -25.83% -10.55%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 6.54 0.00 0.00 0.00 -1,900.57 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -6.00 0.00 0.00 0.00 -853.95 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -63.47 0.00 0.00 0.00 -3,293.36 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -76.02 0.00 0.00 0.00 -2,246.74 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 16.79% 52.38% -270.48% -127.08% -48.10% -14.30% -14.60% -14.81% -13.43% -0.51%

Financials Breakdown Chart

Key Financial Trends

Fulgent Genetics (NASDAQ: FLGT) has shown some notable trends in its financial performance and position over the last four years through Q4 2024.

Revenue and Profitability:

  • Operating revenue has generally increased from about $66 million in early 2023 to over $76 million by Q4 2024, showing steady top-line growth quarter-over-quarter.
  • Despite revenue growth, the company has consistently reported net losses every quarter over the past two years. For example, Q4 2024 net loss was approximately $6.2 million, a large improvement from Q4 2023's loss of $128 million, but still negative.
  • Gross profit has fluctuated but improved somewhat in 2024, reaching $31.8 million in Q4 2024 compared to $25.2 million in Q4 2023.
  • Total operating expenses remain high, roughly consistent near $44-$48 million per quarter in 2024 but spiked significantly in Q4 2023 with an abnormally large expense item, indicating potentially some one-time charges.
  • Interest and investment income remain a significant positive contributor, with about $7.9 million in income in Q4 2024, which mitigates operational losses to some extent.

Cash Flow and Liquidity:

  • Net cash provided by operating activities improved substantially from negative $15.5 million in Q3 2024 to positive $25 million in Q4 2024, showing better operational cash flow management.
  • Net cash used in investing activities remains large and negative, largely driven by substantial investments in securities and property, indicating significant capital deployment ($27 million used in Q4 2024).
  • Net cash from financing activities is slightly negative and relatively minimal compared to operating and investing cash flows, showing low financing impact on cash levels.
  • Cash and equivalents have fluctuated around $50-$65 million range in 2024 quarters, indicating some volatility but maintaining reasonable liquidity.

Balance Sheet Highlights:

  • Total assets stayed stable around $1.2 billion to $1.3 billion, supported by sizeable investments and property assets which indicate strong asset backing.
  • Liabilities remain modest relative to assets, with total liabilities around $90-$100 million, resulting in a strong equity base over $1.1 billion consistently.
  • Shareholders’ equity has remained strong despite ongoing losses, supported by retained earnings and ongoing equity balances near $1.1 billion.

Summary:

Fulgent Genetics has grown revenue steadily in recent quarters, supported by strong investment income and a robust asset base. However, the company continues to generate net losses, though improved compared to the previous year’s extreme losses. Operating cash flow turned positive in the latest quarter after a period of negative cash flow, which is a positive operating sign. Large investment cash outflows suggest an aggressive capital deployment strategy, which may bode well for future growth but could pressure liquidity if losses persist. The company maintains a strong equity position with relatively low liabilities.

Investors should watch for continued improvement in profitability and cash flow as primary indicators of financial health, along with management's ability to turn investments into earnings growth.

10/25/25 12:31 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Fulgent Genetics' Financials

When does Fulgent Genetics' financial year end?

According to the most recent income statement we have on file, Fulgent Genetics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Fulgent Genetics' net income changed over the last 2 years?

Fulgent Genetics' net income appears to be on an upward trend, with a most recent value of -$43.82 million in 2024, falling from $141.92 million in 2022. The previous period was -$175.24 million in 2023. See where experts think Fulgent Genetics is headed by visiting Fulgent Genetics' forecast page.

What is Fulgent Genetics' operating income?
Fulgent Genetics' total operating income in 2024 was -$73.92 million, based on the following breakdown:
  • Total Gross Profit: $107.22 million
  • Total Operating Expenses: $181.13 million
How has Fulgent Genetics' revenue changed over the last 2 years?

Over the last 2 years, Fulgent Genetics' total revenue changed from $618.97 million in 2022 to $283.47 million in 2024, a change of -54.2%.

How much debt does Fulgent Genetics have?

Fulgent Genetics' total liabilities were at $90.81 million at the end of 2024, a 11.0% decrease from 2023, and a 21.8% decrease since 2022.

How much cash does Fulgent Genetics have?

In the past 2 years, Fulgent Genetics' cash and equivalents has ranged from $55.14 million in 2024 to $97.47 million in 2023, and is currently $55.14 million as of their latest financial filing in 2024.

How has Fulgent Genetics' book value per share changed over the last 2 years?

Over the last 2 years, Fulgent Genetics' book value per share changed from 43.03 in 2022 to 37.05 in 2024, a change of -13.9%.


Related Companies

This page (NASDAQ:FLGT) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners
NEW LAW: Congress Approves Setup For Digital Dollar?
Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...
Goldco Precious Metals | Sponsoredtc pixel
If You Keep Cash In A U.S. Bank Account… Read This NOW
The Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...
Banyan Hill Publishing | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...
Brownstone Research | Sponsoredtc pixel
Move $1,000 into this stock before Nov 6
The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...
Altimetry | Sponsoredtc pixel
Buy UBER immediately
BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...
Chaikin Analytics | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel
Front-Run Buffett's Shocking Gold Move
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...
Golden Portfolio | Sponsoredtc pixel